Skip to search formSkip to main contentSkip to account menu

imatinib

Known as: Imatinibum, 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide 
An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (3)

CGP 57148GleevecSTI571
Fusion Proteins, bcr-ablImatinib mesylateMast/Stem Cell Growth Factor Receptor Kit, humanNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Current approach to the treatment of chronic myeloid leukaemia.
Highly Cited
2011
Highly Cited
2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Review
2009
Review
2009
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors… 
Highly Cited
2008
Highly Cited
2008
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition
MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5–10% of primitive myelofibrosis (PMF… 
Highly Cited
2008
Highly Cited
2008
Probiotic prophylaxis in predicted severe acute pancreatitis
Highly Cited
2008
Highly Cited
2008
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
Review
2007
Review
2007
Hydroxyurea chemotherapy in the treatment of meningiomas.
Meningiomas are slow growing, extraaxial tumors that derive from the arachnoidal cap cells of the meninges. Resection remains the… 
Review
2005
Review
2005
Anti-tumour activity of zoledronic acid.
Highly Cited
2003
Highly Cited
2003
Cytogenetic and molecular mechanisms of resistance to imatinib.
  • A. Hochhaus
  • Seminars in hematology (Print)
  • 2003
  • Corpus ID: 20550991
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (Gleevec) (formerly STI571) is a promising new therapeutic… 
Review
2002
Review
2002
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
As described in detail throughout this issue, the BcrAbl tyrosine kinase is a well-validated therapeutic target in chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)